Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00805675
Other study ID # CLDT600AHK01
Secondary ID
Status Completed
Phase Phase 3
First received December 9, 2008
Last updated January 26, 2012
Start date November 2008

Study information

Verified date January 2012
Source Novartis
Contact n/a
Is FDA regulated No
Health authority Hong Kong: Department of Health
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the safety, tolerability and effectiveness of 12 weeks of treatment with telbivudine 600 mg daily plus tenofovir DF 300 mg one daily (OD) taken together vs. tenofovir DF 300 mg once daily (QD) or vs telbivudine 600 mg monotherapy daily (QD). This is an open labeled, active controlled, viral kinetics study which means the subjects and study doctor will know what study drug subjects have been assigned. This study is open to male and female subjects, <40 years of age, who have been infected with HBV for at least 6 months and have not received oral treatment for HBV.


Recruitment information / eligibility

Status Completed
Enrollment 83
Est. completion date
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- Chronic HBV infection, defined as positive serum HBsAg for at least 6 months, or HBsAg positive > 3 months and negative for IgM anti-HBc and positive for IgG anti-HBc

- Age < 40 years old

- HBeAg positive

- HBV DNA > or = to 10^7 copies/mL by Abbott real-time PCR

- ALT < or = to 1 ULN

- Willing and able to provide written informed consent

- No prior oral HBV therapy (e.g., nucleotide and/or nucleoside therapy or other investigational agents for HBV infection)

- Is willing and able to comply with the study drug regimen and all other study procedures and requirements

- Is willing and able to provide written informed consent before any study assessment is perform

Exclusion Criteria:

- Decompensated liver disease defined as direct (conjugated) bilirubin > 1.2 × ULN, PT > 1.2 × ULN, platelets < 150,000/mm3, serum albumin < 3.5 g/dL, or prior history of clinical hepatic decompensation (e.g. ascites, jaundice, encephalopathy, variceal hemorrhage).

- Received interferon (pegylated or not) therapy within 6 months of the screening visit

- a-fetoprotein > 50 ng/mL

- Evidence of hepatocellular carcinoma (HCC)

- Co-infection with HCV (by serology), or HIV,

- Significant renal, cardiovascular, pulmonary, or neurological disease.

- Received solid organ or bone marrow transplantation.

- Is currently receiving therapy with immunomodulators (e.g., corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion.

- Has proximal tubulopathy.

- Use of other investigational drugs at the time of enrollment, or within 30 days

- History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes

- Is pregnant or breastfeeding.

- Is a women of child-bearing potential (WOCBP)unless post-menopausal or using one or more acceptable method of contraception.

- Patient has any other concurrent medical or social condition likely to preclude compliance with the schedule of evaluations in the protocol, or likely to confound the efficacy or safety observations of the study.

- Patient is currently abusing alcohol or illicit drugs, or has a history of alcohol abuse or illicit substance abuse within the preceding two years.

- Patient has a medical condition that requires prolonged or frequent use of systemic acyclovir or famciclovir.

Other protocol-defined inclusion/exclusion criteria may apply

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Telbivudine
600 mg monotherapy supplied in film-coated tablets.
Tenofovir
Tenofovir disoproxil fumarate was supplied in 300 mg tablets
Telbivudine plus tenofovir
Telbivudine 600 mg and Tenofovir 300 mg were purchased in commercial packs. Patients were instructed to take medication(s) orally every morning either with or without food.

Locations

Country Name City State
China Department of Medicine, Queen Mary Hospital Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level From Baseline to Week 12. Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA. Serum HBV DNA determinations were performed at a central laboratory through use of the COBAS TaqMan™ HBV DNA assay (Roche Molecular Systems, Pleasanton, CA, USA) which utilized the Real-time polymerase chain reaction (PCR) method and automated extraction by Cobas Ampliprep (threshold for detection 12 IU/mL). The Screening serum HBV DNA values must be = 7 log10 copies/mL by COBAS TaqMan™ HBV DNA assay. Baseline, Week 12 No
Secondary Change in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level From Baseline to Weeks 2, 4 and 8. Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA. Serum HBV DNA determinations were performed at a central laboratory through use of the COBAS TaqMan™ HBV DNA assay (Roche Molecular Systems, Pleasanton, CA, USA) which utilized the Real-time polymerase chain reaction (PCR) method and automated extraction by Cobas Ampliprep (threshold for detection 12 IU/mL). The Screening serum HBV DNA values must be = 7 log10 copies/mL by COBAS TaqMan™ HBV DNA assay. Baseline, Week 2, Week 4, Week 8 No
Secondary Percentage of Patients Who Are Polymerase Chain Reaction(PCR)Negative at Week 12 Polymerase Chain Reaction (PCR) Negative is defined as HBV DNA levels <25 copies/ml. Week 12 No
Secondary Percentage of Patients Who Achieve Hepatitis B "e" Antigen (HBeAg) Loss and HBeAg Seroconversion at Week 12 HBeAg loss is defined as the loss of detectable serum HBeAg in a patient who was HBeAg positive at baseline. HBeAg seroconversion is defined as HBeAg loss with detectable Hepatitis B 'e' antibody (HBeAb). HBeAg stands for hepatitis B "e" antigen. This antigen is a protein from the hepatitis B virus that circulates in infected blood when the virus is actively replicating. The presence of HBeAg suggests that the person is infectious and is able to spread the virus to other people. Week 12 No
Secondary Characterization of Very Early Viral Kinetics Through Estimated Viral Load The underlying bi-phasic model of viral kinetics can be described as follows:
V(t) (1 )pI(t) cV(t)I(t) (1 ) (T I(t))V(t) I(t)where V denotes serum viral load, I productively infected cells, e the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, ? the efficiency factor of blocking de novo infection, ß the de novo infection rate, Tg comprise all infected and uninfected target cells, and d the rate of infected cell loss
Week 12 No
Secondary Characterization of Very Early Viral Kinetics Through Viral Clearance The underlying bi-phasic model of viral kinetics can be described as follows:
V(t) (1 )pI(t) cV(t)I(t) (1 ) (T I(t))V(t) I(t)where V denotes serum viral load, I productively infected cells, e the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, ? the efficiency factor of blocking de novo infection, ß the de novo infection rate, Tg comprise all infected and uninfected target cells, and d the rate of infected cell loss
Week 12 No
Secondary Characterization of Very Early Viral Kinetics Through Rate of Infected Cell Loss The underlying bi-phasic model of viral kinetics can be described as follows:
V(t) (1 )pI(t) cV(t)I(t) (1 ) (T I(t))V(t) I(t)where V denotes serum viral load, I productively infected cells, e the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, ? the efficiency factor of blocking de novo infection, ß the de novo infection rate, Tg comprise all infected and uninfected target cells, and d the rate of infected cell loss
Week 12 No
Secondary Characterization of Very Early Viral Kinetics Through Efficiency Factor of Blocking Virus Production. The underlying bi-phasic model of viral kinetics can be described as follows:
V(t) (1 )pI(t) cV(t) I(t) (1 ) (T I(t))V(t) I(t) where V denotes serum viral load, I productively infected cells, e the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, ? the efficiency factor of blocking de novo infection, ß the de novo infection rate, Tg comprise allinfected and uninfected target cells, and d the rate of infected cell loss
Week 12 No
Secondary Characterization of Very Early Viral Kinetics Through Half-live of Free Virus The underlying bi-phasic model of viral kinetics can be described as follows:
V(t) (1 )pI(t) cV(t)I(t) (1 ) (T I(t))V(t) I(t)where V denotes serum viral load, I productively infected cells, e the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, ? the efficiency factor of blocking de novo infection, ß the de novo infection rate, Tg comprise all infected and uninfected target cells, and d the rate of infected cell loss
Week 12 No
See also
  Status Clinical Trial Phase
Completed NCT03459521 - Efficacy of HBVaxpro40© and Fendrix© in Patients With Chronic Liver Disease. N/A
Completed NCT02060162 - Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
Completed NCT00912847 - Validity and Cost-Effectiveness of a New Screening Test for Hepatocellular Carcinoma N/A
Completed NCT04072211 - Demonstration Project on Health Care Worker Protection Against Hepatitis B in Kalulushi District Phase 4
Completed NCT01204762 - Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen Phase 2
Completed NCT02785835 - Hepatocellular Carcinoma in HIV-infected Patients
Completed NCT03083821 - A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting Phase 1
Recruiting NCT01083251 - The Beneficial Effect of Vitamin D Supplement to Peg Interferon Alpha 2a or to Telbivudine Monotherapy in Patients With Chronic Hepatitis B Virus (HBV) Infection N/A
Not yet recruiting NCT05752890 - A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma
Recruiting NCT04231565 - Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA. N/A
Terminated NCT00678587 - Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures Phase 3
Completed NCT00739752 - Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics N/A
Completed NCT03294798 - Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient Phase 1/Phase 2
Withdrawn NCT04385524 - Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection N/A
Enrolling by invitation NCT00663182 - Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Phase 4
Completed NCT00769730 - Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral Replication N/A
Completed NCT01438424 - Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials Phase 2
Withdrawn NCT04046107 - Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy Phase 1/Phase 2
Completed NCT05406089 - Effects of Antiviral Therapy on Patients With HBV-related HCC
Completed NCT03625258 - Mutations of the Pre-core Region of Hepatite B Virus (HBV)